Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
Explore this paper's citation graph
Summary
Conurrent NIVO + IPI therapy showed encouraging survival and a manageable safety profile in advanced MEL pts and Responses were observed regardless of BRAF MT status and were durable in the majority of pts.
- Type
- article
- Published
- 2014-06-20
- Cited by
- 161
- References
- 0
- OpenAlex
- https://openalex.org/W2246441943
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:20586637
Keywords
Medicine, Ipilimumab, Nivolumab, Internal medicine, Cohort
References
No references recorded for this paper.
Cited by
- Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma
- Systemic therapy of metastatic melanoma: on the road to cure.
- Prospects for targeting PD-1 and PD-L1 in various tumor types.
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- Long term Survival with CTLA-4 blockade Using Tremelimumab
- Clinical Development of Immune Checkpoint Inhibitors
- Nivolumab in the treatment of advanced melanoma
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- New Strategies in Melanoma: Entering the Era of Combinatorial Therapy
- The Promise of Preventive Cancer Vaccines
- The Use of Anti-CD40 mAb in Cancer.
- Evolving synergistic combinations of targeted immunotherapies to combat cancer
- Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
- Trametinib in metastatic melanoma
- Cancer Immunotherapy: Past Progress and Future Directions.
- Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
- Multiplying therapies and reducing toxicity in metastatic melanoma
- A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
Related papers
- Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
- Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
- Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer
- Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
- Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
- Nivolumab in melanoma
- 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
- Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
- 1050P Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors